{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:29:34Z","timestamp":1795026574301,"version":"4.10.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28\u2009days after a first dose of ChAdOx1nCoV-19 (<jats:italic>n<\/jats:italic>\u2009=\u200920,417,752) or BNT162b2 (<jats:italic>n<\/jats:italic>\u2009=\u200912,134,782), and after a SARS-CoV-2-positive test (<jats:italic>n<\/jats:italic>\u2009=\u20092,005,280). There was an increased risk of Guillain\u2013Barr\u00e9 syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15\u20133.92 at 15\u201321\u2009days after vaccination) and Bell\u2019s palsy (IRR, 1.29; 95% CI: 1.08\u20131.56 at 15\u201321\u2009days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12\u20131.71 at 15\u201321\u2009days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain\u2013Barr\u00e9 syndrome (IRR, 2.32; 95% CI: 1.08\u20135.02 at 1\u201328\u2009days). There was a substantially higher risk of all neurological outcomes in the 28\u2009days after a positive SARS-CoV-2 test including Guillain\u2013Barr\u00e9 syndrome (IRR, 5.25; 95% CI: 3.00\u20139.18). Overall, we estimated 38 excess cases of Guillain\u2013Barr\u00e9 syndrome per 10\u2009million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10\u2009million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test.<\/jats:p>","DOI":"10.1038\/s41591-021-01556-7","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T16:02:36Z","timestamp":1635177756000},"page":"2144-2153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":352,"title":["Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection"],"prefix":"10.1038","volume":"27","author":[{"given":"Martina","family":"Patone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-3722","authenticated-orcid":false,"given":"Lahiru","family":"Handunnetthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defne","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-9092","authenticated-orcid":false,"given":"Srinivasa Vittal","family":"Katikireddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2307-550X","authenticated-orcid":false,"given":"Saif","family":"Razvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-0207","authenticated-orcid":false,"given":"David","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-4884","authenticated-orcid":false,"given":"Xue W.","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Watkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A. C.","family":"Coupland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-3100","authenticated-orcid":false,"given":"James","family":"Doidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-9024","authenticated-orcid":false,"given":"Rommel","family":"Ravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-3056","authenticated-orcid":false,"given":"Aziz","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-7283","authenticated-orcid":false,"given":"Julia","family":"Hippisley-Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case\u2013control study. BMJ 373, n1088 (2021).","journal-title":"BMJ"},{"key":"1556_CR2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","volume":"397","author":"E Vasileiou","year":"2021","unstructured":"Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646\u20131657 (2021).","journal-title":"Lancet"},{"key":"1556_CR3","doi-asserted-by":"publisher","first-page":"JC29","DOI":"10.7326\/ACPJ202103160-029","volume":"174","author":"Z Chagla","year":"2021","unstructured":"Chagla, Z. In adults, the Oxford\/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose. Ann. Intern. Med. 174, JC29 (2021).","journal-title":"Ann. Intern. Med."},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1556_CR5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412\u20131423 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1556_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect. Dis. 21, 939\u2013949 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1556_CR7","doi-asserted-by":"publisher","first-page":"n1114","DOI":"10.1136\/bmj.n1114","volume":"373","author":"A Pottegard","year":"2021","unstructured":"Pottegard, A. et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 373, n1114 (2021).","journal-title":"BMJ"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"n1931","DOI":"10.1136\/bmj.n1931","volume":"374","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox, J. et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 374, n1931 (2021).","journal-title":"BMJ"},{"key":"1556_CR9","doi-asserted-by":"publisher","first-page":"e242956","DOI":"10.1136\/bcr-2021-242956","volume":"14","author":"SU Patel","year":"2021","unstructured":"Patel, S. U., Khurram, R., Lakhani, A. & Quirk, B. Guillain\u2013Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 14, e242956 (2021).","journal-title":"BMJ Case Rep."},{"key":"1556_CR10","doi-asserted-by":"publisher","unstructured":"Singh Malhotra, H. et al. COVID-19 vaccination-associated myelitis. QJM https:\/\/doi.org\/10.1093\/qjmed\/hcab069 (2021).","DOI":"10.1093\/qjmed\/hcab069"},{"key":"1556_CR11","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1007\/s00415-021-10462-4","volume":"268","author":"G Colella","year":"2021","unstructured":"Colella, G., Orlandi, M. & Cirillo, N. Bell\u2019s palsy following COVID-19 vaccination. J. Neurol. 268, 3589\u20133591 (2021).","journal-title":"J. Neurol."},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2215-0366(20)30287-X","volume":"7","author":"A Varatharaj","year":"2020","unstructured":"Varatharaj, A. et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7, 875\u2013882 (2020).","journal-title":"Lancet Psychiatry"},{"key":"1556_CR13","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/brain\/awaa240","volume":"143","author":"RW Paterson","year":"2020","unstructured":"Paterson, R. W. et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 143, 3104\u20133120 (2020).","journal-title":"Brain"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/oxfordjournals.aje.a008695","volume":"143","author":"CP Farrington","year":"1996","unstructured":"Farrington, C. P., Nash, J. & Miller, E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am. J. Epidemiol. 143, 1165\u20131173 (1996).","journal-title":"Am. J. Epidemiol."},{"key":"1556_CR15","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen, I., Douglas, I. & Whitaker, H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 354, i4515 (2016).","journal-title":"BMJ"},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ana.26143","volume":"90","author":"BV Maramattom","year":"2021","unstructured":"Maramattom, B. V. et al. Guillain-Barre syndrome following ChAdOx1-S\/nCoV-19 vaccine. Ann. Neurol. 90, 312\u2013314 (2021).","journal-title":"Ann. Neurol."},{"key":"1556_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.26144","volume":"90","author":"CM Allen","year":"2021","unstructured":"Allen, C. M. et al. Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination. Ann. Neurol. 90, 315\u2013318 (2021).","journal-title":"Ann. Neurol."},{"key":"1556_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ajh.26132","volume":"96","author":"EJ Lee","year":"2021","unstructured":"Lee, E. J. et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am. J. Hematol. 96, 534\u2013537 (2021).","journal-title":"Am. J. Hematol."},{"key":"1556_CR19","doi-asserted-by":"publisher","first-page":"E133","DOI":"10.1002\/ajh.26106","volume":"96","author":"O Tarawneh","year":"2021","unstructured":"Tarawneh, O. & Tarawneh, H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am. J. Hematol. 96, E133\u2013E134 (2021).","journal-title":"Am. J. Hematol."},{"key":"1556_CR20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","volume":"67","author":"C Walgaard","year":"2010","unstructured":"Walgaard, C. et al. Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann. Neurol. 67, 781\u2013787 (2010).","journal-title":"Ann. Neurol."},{"key":"1556_CR21","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1136\/jnnp-2014-309056","volume":"86","author":"AJ Webb","year":"2015","unstructured":"Webb, A. J., Brain, S. A., Wood, R., Rinaldi, S. & Turner, M. R. Seasonal variation in Guillain-Barre syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J. Neurol. Neurosurg. Psychiatry 86, 1196\u20131201 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1556_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/pds.3337","volume":"22","author":"K Wilson","year":"2013","unstructured":"Wilson, K. & Hawken, S. Drug safety studies and measures of effect using the self-controlled case series design. Pharmacoepidemiol. Drug Saf. 22, 108\u2013110 (2013).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1556_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch, M., Tchetgen Tchetgen, E. & Cohen, T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21, 383\u2013388 (2010).","journal-title":"Epidemiology"},{"key":"1556_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/vaccines9030221","volume":"9","author":"NG Kounis","year":"2021","unstructured":"Kounis, N. G. et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines (Basel) 9, 221 (2021).","journal-title":"Vaccines"}],"updated-by":[{"DOI":"10.1038\/s41591-021-01644-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01556-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T18:28:36Z","timestamp":1699727316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01556-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01556-7","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41591-021-01644-8","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-021-01644-8","URL":"https:\/\/doi.org\/10.1038\/s41591-021-01644-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S. is a member of the Scottish Government Chief Medical Officer\u2019s COVID-19 Advisory Group, the Scottish Government\u2019s Standing Committee on Pandemics, and AstraZeneca\u2019s Thrombotic Thrombocytopenic Advisory Group. All roles are unremunerated. D.H. is a member of the Commission on Human Medicine\u2019s Neurology, Pain and Psychiatry Expert Advisory Group. K.K. is a member of the Government Scientific Advisory Group for Emergencies. C.R. is a member of the Scottish Government Chief Medical Officer\u2019s COVID-19 Advisory Group, SPI-M, and the MHRA Vaccine Benefit and Risk Committee. J.H.-C. reports grants from the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CR-UK) (grant number C5255\/A18085), through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund (204826\/Z\/16\/Z) and other research councils, during the conduct of the study. J.H.-C. is an unpaid director of QResearch, a not-for-profit organization that is a partnership between the University of Oxford and EMIS Health, who supply the QResearch database used for this work. J.H.-C. is a founder and shareholder of ClinRisk Ltd and was its medical director until 31 May 2019. ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. J.H.-C. is chair of the NERVTAG risk stratification subgroup and a member of SAGE COVID-19 groups and the NHS group advising on prioritization of use of monoclonal antibodies in COVID-19 infection. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}